Table 3.
Distribution of resistance-phenotypes among GBS serotypes isolated from Iran (January – April, 2008).
| Serotype ( n) | Resistance-phenotype | |
|---|---|---|
|
| ||
| Resistant (%) | Intermediate (%) | |
| Ia (4) | CO (100) | CI (100), CF (75) |
| Ib (5) | CO (100), CF (40), CI (20) | CI (80), CF (60) |
| II (7) | CO (85), CF (14), CI (14), CM (14.28) | CO (14), CF (85), CI (85), EM (14.28) |
| III (6) | CO (66), CF (33), CI (33), CM (16.66) | CF (40), CI (20), CZ (13) |
| IV (7) | CO (66) | CI (85), CF (85) |
| V (11) | CO (90), CF (9), CI (18), | CI (72), CF (81), EM (9.09), CM (18.18) |
| VI (6) | CO (100), CI (16) | CI (66), CF (100) |
| VII (3) | CI (66), CF (33) | CI (100), CF (66) |
| VIII (3) | CO (100) | CI (66), CF (66) |
| NTa (4) | CO (75), CF (25) | CF (75), CI (50), EM (25) |
Abbreviation: CO. Co-trimoxazole; CI. Ceftriaxone; CF. Ciprofloxacin; CM. Clindamycin; EM. Erythromycin; CZ. Cefazolin
a
Non-typable